Deadline for abstract submission: 11 February 2020
Authors are invited to submit their abstract via the abstract submission form available on this web site. Abstracts can be saved in “Draft” status to be modified until the submission deadline (11 February 2020). The submitter will be required to create a user account.
Abstracts can only be submitted online via the abstract submission form. Abstracts sent by post or email or fax will not be accepted.
The abstract, in English or Italian, should be structured into the following sections:
- Materials and Methods
- Discussion and Conclusions
The length of the abstract is of maximum 3,300 characters, spaces included (excluding title, authors and institutions).
No pictures or graphs should be included in the abstract.
The title and body text must not contain authors’ names and institutions. Do not use commercial drug names in the abstract. Drugs should be referred to by the active substance.
Do not include abbreviations in the title. Define all abbreviations in your abstract text at first use.
All abstracts submitted within the deadline go through a blind peer-review process, carried out by a committee of referees and will be than selected by the Congress Scientific Committee according to the following criteria:
- Scientific interest
- Validity of materials and method
- Completeness of the results
- Statistical Study
- Oral Communication
In case of acceptance, the Scientific Committee reserves the right to propose an alternative presentation type for the abstract.
Notifications of acceptance or rejection of abstracts and guidelines for oral presentations and e-posters will be sent to the corresponding author of the abstract by 23 February 2020.
The Abstract presenting author must upload together with the abstract his curriculum vitae (signed and dated) and must be registered to the congress.
- Neuromuscular deformities
- Deformity: scoliosis and kyphosis
- Degenerative pathology
- Basic research
- New technologies